Herbal medicines and nonalcoholic fatty liver disease

Yao, Hong; Qiao, Yujie; Zhao, Yongliang; Tao, Xufeng; Xu, Lina; Yin, Lianhong; Yan, Qi; Peng, Jinyong

doi:10.3748/wjg.v22.i30.6890

Cited by 121 publications

(68 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In China, over 200 million people may have NAFLD, and among them, 40 to 120 million might have NASH . However, the majority of clinical trials have focused on investigating the effects of TCM, herbal extracts, antidiabetic agents, and probiotics for the treatment of NAFLD.…”

Section: Resultsmentioning

confidence: 99%

Epidemiological Features of NAFLD From 1999 to 2018 in China

et al. 2020

View full text Add to dashboard Cite

With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NaFlD) has become the most prevalent liver disorder in China but has not received sufficient attention. NaFlD-related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. there is thus an imperative need to clarify the epidemiological features of NaFlD to guide a holistic approach to management. We summarize eight epidemiological features of NaFlD in China over the past two decades using systematic review and meta-analysis methodology. our data reveal a rapid growth in the NaFlD population, especially among younger individuals. Importantly, there is a strong ethnic difference in body mass index (BMI) and genetic risk of NaFlD compared with the US population. the etiology of advanced liver disease and its complications (e.g., hepatocellular carcinoma) has been altered because of a Westernized lifestyle and the implementation of effective vaccination strategies against viral hepatitis. Regional epidemiological patterns of NaFlD indicate that economics, environment, and lifestyle are critical factors in disease progression. the analysis also indicates that a large number of patients remain undiagnosed and untreated because of the inadequacy of diagnostic tools and the absence of effective pharmacologic therapies. given the burden of NaFlD, future policy and research efforts need to address knowledge gaps to mitigate the risk burden.

show abstract

Section: Resultsmentioning

confidence: 99%

Epidemiological Features of NAFLD From 1999 to 2018 in China

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Pure natural products, as carriers of modern herbal medicine advanced technology, are considered as the only way for TCM to realize modernization and internationalization (Normile, 2003; Yao et al, 2016b). Natural products have been used in Japan since the 1970s and have been widely developed in Singapore and other places (Normile, 2003).…”

Section: Pleiotropic Natural Productsmentioning

confidence: 99%

Chinese Herbal Medicines Attenuate Acute Pancreatitis: Pharmacological Activities and Mechanisms

Xiang

Zhang

et al. 2017

Front. Pharmacol.

View full text Add to dashboard Cite

Acute pancreatitis (AP) is a commonly occurring gastrointestinal disorder. An increase in the annual incidence of AP has been observed, and it causes acute hospitalization and high mortality. The diagnosis and treatment guidelines for AP recommend conservative medical treatments focused on reducing pancreatic secretion and secondary injury, as a primary therapeutic approach. Unfortunately, the existing treatment options have limited impact on the incidence and severity of AP due to the complex and multifaceted pathological process of this disease. In recent decades, Chinese herbal medicines (CHMs) have been used as efficient therapeutic agents to attenuate AP in Asian countries. Despite early cell culture, animal models, and clinical trials, CHMs are capable of interacting with numerous molecular targets participating in the pathogenesis of AP; however, comprehensive, up-to-date communication in this field is not yet available. This review focuses on the pharmacological activities of CHMs against AP in vitro and in vivo and the underlying mechanisms. A computational prediction of few selected and promising plant-derived molecules (emodin, baicalin, resveratrol, curcumin, ligustrazine, and honokiol) to target numerous proteins or networks involved in AP was initially established based on a network pharmacology simulation. Moreover, we also summarized some potential toxic natural products for pancreas in order to more safe and reasonable medication. These breakthrough findings may have important implications for innovative drug research and the future development of treatments for AP.

show abstract

“…Naturally, NAFLD is a heterogeneous disease, and a full understanding of the mechanisms contributing to progression risk in NAFLD is vital for providing clarity in this regard. The spectrum of NAFLD ranges from simple steatosis to advanced stages, including nonalcoholic steatohepatitis (NASH), hepatic fibrosis, and cirrhosis . Different theories have been pointed out, leading initially to the “two‐hit hypothesis.” The first hit is insulin resistance (IR) and lipotoxicity causing hepatocyte injury, but a second hit is needed for chronic liver damage and includes apoptosis, oxidative stress, and lipid peroxidation .…”

mentioning

confidence: 99%

Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal–Regulating Kinase 1 Pathways

Huang

Zhang

et al. 2019

Hepatology

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide. Due to the growing economic burden of NAFLD on public health, it has become an emergent target for clinical intervention. DUSP12 is a member of the dual specificity phosphatase (DUSP) family, which plays important roles in brown adipocyte differentiation, microbial infection, and cardiac hypertrophy. However, the role of DUSP12 in NAFLD has yet to be clarified. Here, we reveal that DUSP12 protects against hepatic steatosis and inflammation in L02 cells after palmitic acid/oleic acid treatment. We demonstrate that hepatocyte specific DUSP12-deficient mice exhibit high-fat diet (HFD)-induced and high-fat high-cholesterol diet-induced hyperinsulinemia and liver steatosis and decreased insulin sensitivity. Consistently, DUSP12 overexpression in hepatocyte could reduce HFDinduced hepatic steatosis, insulin resistance, and inflammation. At the molecular level, steatosis in the absence of DUSP12 was characterized by elevated apoptosis signal-regulating kinase 1 (ASK1), which mediates the mitogenactivated protein kinase (MAPK) pathway and hepatic metabolism. DUSP12 physically binds to ASK1, promotes its dephosphorylation, and inhibits its action on ASK1-related proteins, JUN N-terminal kinase, and p38 MAPK in order to inhibit lipogenesis under high-fat conditions. Conclusion: DUSP12 acts as a positive regulator in hepatic steatosis and offers potential therapeutic opportunities for NAFLD. (Hepatology 2019;70:1099-1118). SEE EDITORIAL ON PAGE 1091N onalcoholic fatty liver disease (NAFLD) is the most common diffuse liver disease and is characterized by lipid accumulation in hepatocytes in the absence of excessive alcohol consumption. (1) The prevalence of NAFLD increases worryingly with obesity and other diseases of metabolic syndrome (MS) and is expected to be the leading cause of liver failure in the future. (2) Accumulating studies show that NAFLD not only is linked to an increased risk of liver-related mortality or morbidity

show abstract

Herbal medicines and nonalcoholic fatty liver disease

Cited by 121 publications

References 168 publications

Epidemiological Features of NAFLD From 1999 to 2018 in China

Epidemiological Features of NAFLD From 1999 to 2018 in China

Chinese Herbal Medicines Attenuate Acute Pancreatitis: Pharmacological Activities and Mechanisms

Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal–Regulating Kinase 1 Pathways

Contact Info

Product

Resources

About